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Abstract In this study, the interaction of ruptured cardiac 
myocytes with low density lipoprotein (LDL) has been investi-
gated and the consequent extent of uptake by macrophages. The 
results show that lysate released from ruptured myocytes is 
capable of inducing LDL oxidation and that the resulting 
modified form is recognised and degraded by macrophages. 
Peroxyl radical scavengers inhibit the LDL oxidation but not the 
macrophage uptake suggesting that LDL can be modified by 
mechanisms that are independent of oxidative processes by 
intracellular constituents of cardiac myocytes. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
There is much evidence supporting the hypothesis that ox-
idative modification of low density lipoprotein (LDL) in the 
arterial wall may contribute towards the pathogenesis of athe-
rosclerosis, although the mechanism by which this occurs in 
vivo is still far from clear. The presence of oxidatively modi-
fied LDL has been demonstrated in atherosclerotic lesions and 
LDL eluted therefrom, but not LDL from normal arteries, is 
rapidly taken up by the scavenger receptors of macrophages 
[!]■ 
Studies in vitro have shown that LDL can be oxidatively 
modified by peroxynitrite [2], lipoxygenäse [3], haem proteins 
[4,5] and all the major cell types found in the arterial wall: 
macrophages [6,7], monocytes [8], endothelial cells [9], smooth 
muscle cells [10] and lymphocytes [11], and recent work is 
demonstrating that the recognition properties of LDL can 
also be modified by non-oxidative mechanisms such that it 
is taken up by target macrophages [12-14]. 
Since release of myoglobin from ruptured cardiac myocytes 
is an early indicator of myocardial infarction, the interaction 
of ruptured cardiac myocytes with LDL has been investigated 
and the consequent altered recognition properties and uptake 
by macrophages. The results show that lysate released from 
ruptured myocytes is capable of inducing LDL oxidation and 
that the resulting modified form is recognised and degraded 
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by macrophages. Peroxyl radical scavengers inhibit the LDL 
oxidation but not the macrophage uptake suggesting that 
LDL can be modified by mechanisms that are independent 
of oxidative processes by intracellular constituents of cardiac 
myocytes. 
2. Materials and methods 
All chemicals used were of the analytical grade. Low density lipo-
proteins were isolated from human plasma using the modified method 
of Chung et al. [15] and dialysed in 10 mM phosphate buffered saline, 
pH 7.4 (PBS), containing EDTA (10 μΜ). The concentration of LDL 
protein was estimated according to Markwell et al. [16]. Low density 
lipoproteins were labelled with Na125I using iodine monochloride as 
described by McFarlane [17] as modified by Bilheimer et al. [18]. The 
iodinated LDL was mixed immediately after labelling with the non-
iodinated LDL to obtain a preparation of specific activity 30-60 cpm/ 
ng protein. [125I]LDL prepared by this method had the same electro-
phoretic mobility as the corresponding unlabelled native LDL from 
which it was derived. 
Equine myoglobin was purified on a Sephadex G-25 column, after 
oxidation with excess of potassium ferricyanide, and the concentration 
of metmyoglobin determined spectrophotometrically [19]. Oxymyo-
globin was purified on a Sephadex G-25 column, after reduction 
with excess sodium dithionite [20]. 
LDL oxidation was assessed by monitoring formation of lipid hy-
droperoxides and the altered surface charge in the apolipoprotein B-
100. Relative electrophoretic mobility (REM) which is an index of the 
surface charge of apolipoprotein B-100 was measured using the Beck-
man Paragon LIPO electrophoresis kit and calculated as the ratio of 
the electrophoretic mobility of the treated samples to that of control 
incubated LDL. 
Lipid peroxidation was measured by determining lipid hydroperox-
ides using the FOX assay [21]. Briefly, to 90 μΐ sample (125 μg LDL 
protein/ml) 10 μΐ of distilled water was added and the sample mixed. 
900 μΐ of FOX reagent (250 μΜ ammonium ferrous sulphate, 100 μΜ 
xylenol orange, 25 mM H2S04 and 4 mM butylated hydroxytoluene 
(BHT, in 90% (v/v) methanol) was added and the sample incubated at 
room temperature for 30 min. The sample was centrifuged and the 
absorbance read at 560 nm. Duplicate samples were treated with 
triphenylphosphine (a reductant of hydroperoxides to discriminate 
any constituents that give an absorbance at 560 nm but are not hydro-
peroxides), incubated for 30 min at room temperature and treated as 
described. The difference between the sample with and without tri-
phenylphosphine gives the level of lipid hydroperoxide. The working 
reagent was routinely calibrated against solutions of H2O2 of known 
concentration. 
Resident peritoneal macrophages were isolated from female Swiss 
T.O. mice (A. Tuck and Son, Battlesbridge, Essex, UK) by a mod-
ification of the method of Cohn and Benson [22]. The cells were 
plated in 22 mm diameter wells in 12 well cluster plates (Costar, 
from Northumbria Biologicals Ltd, Cramlington, Northumbria, 
UK) at 1X 106 peritoneal cells per well. The plated cells were incu-
bated at 37°C under 5% CO2 for 2-4 h to allow macrophage adher-
ence, then washed in Dulbecco's modified Eagle's medium (DMEM; 
containing 10% fetal calf serum and 50 μg gentamicin/ml) to remove 
lymphocytes before use. J774 cells were obtained from Dr D.T. Hart 
(Life Sciences Division, King's College, London) and were grown in 
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DMEM containing 20% (v/v) fetal calf serum, 10 μg streptomycin/ml, 
10 IU penicillin/ml and 5 μg amphotericin/ml. 
Cardiac myocytes were isolated from adult male Wistar rats by the 
method of Powell et al. [23]. The myocytes were prepared by the 
proteolytic disruption of Langendorff perfused hearts. The intact 
heart was perfused in the Langendorff mode with a low calcium buff-
er, in order to flush the coronary vasculature of blood. After 5 min, 
the heart was perfused with buffer containing a mixture of proteolytic 
enzymes [collagenase A (140 μg/ml; Sigma); protease XIV (30 μg/ml; 
Sigma)] in order to degrade the extracellular matrix and separate the 
intercellular junctions. The heart was finally perfused with buffer to 
remove any residual enzyme and the tissue disrupted mechanically. 
The myocytes in buffer were lysed by sonication (MSE Probe sonica-
tor) for 2 min on ice. The membranes were removed from the myocyte 
lysate by centrifugation at 105000Xg for 1 h. The concentration of 
myoglobin was assessed by measurement of the absorbance of the 
supernatant at 414 nm after subtraction of the background absorb-
ance at 700 nm [24]. 
Metmyoglobin and oxymyoglobin were prepared as described 
above. Following purification and quantification the myoglobin was 
sterilised by membrane filtration (0.22 μpiι pore size). Ferryl myoglo-
bin was prepared by activation of metmyoglobin with hydrogen per-
oxide (molar ratio 1:1.25). PBS 10 mM used in the incubation was 
also sterilised by filtration. 
125I-Labelled LDL (100 μg protein/ml) was incubated with metmyo-
globin 4 μΜ, oxymyoglobin 4 μΜ or ferryl myoglobin (formed from 
metmyoglobin 4 μΜ and hydrogen peroxide 5 μΜ) or myocyte lysate 
at a final concentration of myoglobin of 4 μΜ in PBS for 22 h at 37°C 
in a humidified 5% CC>2/95% air incubator. After 22 h the oxidised, 
control and native 125I-labelled LDL were diluted in triplicate to 10 μg 
protein/ml in DMEM containing serum and gentamicin. The fetal calf 
serum in the medium prevents any further oxidation of the LDL at 
this stage [7]. The diluted 125I-labelled LDL was added in triplicate to 
monolayers of macrophages or into cell-free 22 mm multiwell cluster 
plates and incubated for 22 h at 37°C in a humidified 5% CO2 in-
cubator. The rate of uptake followed by lysosomal degradation was 
estimated by the measurement of the release of radioactive non-iodide 
trichloroacetic acid-soluble degradation products into the medium [7]. 
The effects of antioxidants and of competition for the scavenger 
receptors on the uptake of 125I-labelled LDL modified by a myocyte 
lysate by mouse peritoneal macrophages was assessed essentially as 
above. BHT (in ethanol) was added to inhibit oxidation at a final 
concentration of 15 μΜ. The effect of a protease inhibitor on the 
uptake by mouse peritoneal macrophages of 126I-labelled LDL modi-
fied by a myocyte lysate was investigated by applying chymostatin to 
the lysates. Protease XIV is used in the isolation of the myocytes and 
it has been shown that proteolytic damage to LDL can result in 
uptake by macrophages [25]. Thus myocyte lysate was prepared by 
perfusión with collagenase alone, as well as with protease XIV plus 
collagenase. 
3. Results 
The oxidation of L D L (250 μg protein/ml) by lysate re-
leased from ruptured myocytes (10 μ Μ myoglobin) was as-
Table 1 
Effects of various myoglobin forms on the oxidation of LDL 
Table 2 
Effects of myoglobins on the modification of LDL leading to in-
creased macrophage uptake 
Degradation of 125I-labelled LDL 
^ g LDL protein/mg cell protein in 22 h) 
Control LDL 
Oxymyoglobin 
Metmyoglobin 
Ferryl myoglobin 
Myocyte lysate 
Lipid hydroperoxides 
(nmol/mg LDL protein) 
7 ±0.005 
418±4 
342 ±0.03 
319±4 
18±0.7 
REM 
1 
3.3 
3.7 
3.7 
1.4 
LDL (250 μg protein/ml) was incubated with 10 μΜ metmyoglobin, 
10 μΜ oxymyoglobin, 10 μΜ metmyoglobin plus 12.5 μΜ hydrogen 
peroxide to generate ferryl myoglobin and myocyte lysate (final con-
centration of myoglobin 10 μΜ) at 37°C for 15 h for these compar-
ison studies. The lipid hydroperoxides were then measured by the 
FOX assay. The results shown are the means of triplicate determina-
tions ± S.D. but are representative of three independent experiments. 
Native LDL 
Control LDL 
Oxymyoglobin 
Metmyoglobin 
Ferryl myoglobin 
Myocyte lysate 
0.341 ±0.03 
0.347 ±0.017 
0.556 ±0.012 
0.693 ±0.076 
1.018±0.112 
1.50 ±0.25 
125I-Labelled LDL (100 μg protein/ml) was incubated with myoglobin 
(Mb 4 μΜ) and myocyte lysate (Mb 4 μΜ) for 22 h at 37°C. Myo-
globin-modified, control and native 125I-labelled LDL were diluted to 
10 μg protein/ml in serum-containing medium and its degradation by 
J774 cells determined. The means ± S.E.M. are shown but are repre-
sentative of four independent experiments. 
sessed by production of hydroperoxides and the alteration in 
the surface charge on the apolipoprotein B-100 (Table 1) in 
comparison with the extent of oxidation promoted by ferryl, 
met- and oxymyoglobin with a similar myoglobin concentra-
tion. Under these conditions, myocyte myoglobin was less 
effective than free myoglobin preparations in catalysing oxi-
dation of lipids. The apolipoprotein B-100 of LDL showed 
increased negative charge after oxy-, met- or ferryl myoglobin-
promoted oxidation, but a considerably lower increase from 
myocyte lysate. 
The recognition properties of the oxidised LDL by scav-
enger receptors on J774 macrophages was investigated. Up-
take of 125I-labelled LDL modified by myoglobin (4 μΜ) was 
measured by the release of radioactive non-iodide TCA-solu-
ble degradation products into the medium (Table 2). LDL 
pre-oxidised by ferryl, met- and oxymyoglobin (4 μΜ) for 
22 h was also taken up faster by macrophages, the hierarchy 
of degradation of the modified LDL paralleling the oxidation 
profile of ferryl, met and oxy. However, LDL modified by 
myocyte lysate was degraded more rapidly than the myoglo-
bin-modified LDL and yet the extent of oxidation by myocyte 
lysate in terms of lipid hydroperoxides was much less than 
with myoglobin as shown in Table 1. Furthermore, the mod-
ification of the surface charge on the apolipoprotein B-100 
was minimal with the same concentration of myocyte lysate 
as compared with met-, oxy- and ferryl myoglobin, thus the 
former might be expected to show limited uptake by macro-
phages. 
In order to elucidate whether the greater extent of degra-
dation of LDL modified by myocyte lysate was due to mech-
anisms that are independent of oxidation, the effect of BHT, a 
chain-breaking antioxidant, on the degradation by macro-
phages was investigated. At this stage the J774 cell line was 
replaced by mouse peritoneal macrophages in order that poly-
inosinic acid could be applied as a competitive inhibitor of the 
scavenger receptors. (The scavenger receptors on J774 cells 
may be different from those on mouse peritoneal macro-
phages, Stait and Leake, unpublished observations.) The re-
sults demonstrate that the addition of the antioxidant BHT to 
the myocyte lysate did not inhibit the modification of the 
LDL to a form that was subsequently degraded faster by 
macrophages (Table 3) and yet the increase in electrophoretic 
mobility was prevented. The increased uptake by macro-
phages therefore was apparently not as a result of lipid per-
oxidation but as a result of a non-oxidative process. The 
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Table 3 
Effects of BHT and polyinosinic acid on the modification of LDL by a myocyte lysate and its degradation by macrophages 
Degradation of 125I-labelled LDL 
^ g LDL protein/mg cell protein in 22 h) 
Native LDL 
Control LDL 
LDL+myocyte lysate 
LDL+myocyte lysate+BHT (15 μΜ) 
LDL+myocyte lysate+Poly I (18 μg/ml) 
0.6 ±0.03 
0.7 ±0.05 
1.7 ±0.08 
1.8 ±0.09 
2.8 ±0.02 
REM 
1.6 
125I-Labelled LDL (100 μg protein/ml) was incubated with myocyte lysate (Mb 4 μΜ) with or without BHT, for 22 h at 37°C. Myocyte lysate-
modified, control and native 125I-labelled LDL were diluted to 10 μg protein/ml in serum-containing medium and incubated with mouse peritoneal 
macrophages (1X 10° peritoneal cells/ml), with or without polyinosinic acid, or in cell-free wells for 22 h at 37°C. The means ± S.E.M. are shown 
but are representative of three independent experiments. 
addition of polyinosinic acid (18 μ^ηιΐ) to the macrophages, 
to inhibit competitively the scavenger receptors of macro-
phages [7], did not reduce the degradation but increased it. 
It was deduced that the uptake of myocyte lysate-modified 
LDL was not via the type A scavenger receptor, cloned by 
Kodama et al. [26], but by another receptor. 
The question might be posed as to whether a protease from 
within the myocytes or used in their preparation was damag-
ing the LDL and increasing its uptake by macrophages. Pre-
vious studies have shown that proteolysis of LDL results in 
aggregation and enhanced uptake by macrophages [25,27] and 
others have shown that proteases especially cathepsin D in 
myocyte lysosomes may be released on sonication [28]. In 
addition, during the isolation of myocytes, protease (type 
XIV) is used during the digestion and it might be postulated 
that trace amounts may be present in the myocyte lysate, thus 
damaging the LDL and resulting in aggregation and its in-
creased uptake by macrophages. Thus the effect of adding 
chymostatin, a protease inhibitor, to myocyte lysate was in-
vestigated on the subsequent degradation of the LDL by mac-
rophages. The results show that there were no significant dif-
ferences in the modification of 125I-labelled LDL in the 
presence of chymostatin (Table 4). Once again LDL in the 
presence of myocyte lysate showed an increased rate of up-
take, and the addition of BHT did not inhibit modification. In 
addition, myocyte lysate, prepared in the presence of collage-
nase only, was capable of modifying LDL to a form that had 
an increased rate of degradation by macrophages (results not 
shown). 
To elucidate the possible mechanism of the non-oxidative 
process involved, and whether protease or lipoprotein lipase 
activities were involved, the effect of pH on the modification 
of 125I-labelled LDL by myocyte lysate, was investigated. The 
myocyte lysate was prepared without protease (type XIV) to 
eliminate any possible interference. 125I-Labelled LDL (100 μg 
protein/ml) was incubated with myocyte lysate at a final con-
centration of myocyte myoglobin of 4 μΜ in PBS at pH 4, 
5.5, 7.4, 8.5 and 10 for 22 h at 37°C. The results (Table 4) 
show that the modification of LDL by a myocyte lysate was 
pH dependent. The modification was favoured at acidic pH. 
At pH 7.4, the addition of 10 μΜ EDTA and chymostatin (30 
μg/ml) had no effect on the rate of modification. Furthermore 
with 125I-labelled LDL modified at pH 7.4, the addition of 
excess unlabelled LDL to the macrophages, to competitively 
inhibit the LDL receptor, had only a fairly small effect on the 
rate of degradation, thus the uptake was not via the LDL 
receptor. 
4. Discussion 
Previous studies have shown that LDL can be oxidatively 
modified by oxy-, metO and ferryl myoglobin [4,29,30]. The 
results described here show further that such oxidatively 
modified LDL is recognised and taken up by macrophages. 
There was, as seen in previous studies, a hierarchy in the ferryl 
myoglobin-modified LDL was degraded more extensively than 
metmyoglobin-modified which was degraded more than oxy-
myoglobin-modified LDL. It was reported [4] that the relative 
differences in the oxidation with met- and ferryl were indis-
tinguishable after 14 h. However, these experiments clearly 
Table 4 
Effects of pH on the modification of LDL by a myocyte lysate 
Degradation of 125I-labelled LDL by macrophages 
(jig LDL protein/mg cell protein in 22 h) 
pH4 
pH 5.5 
pH 7.4 
pH 8.5 
pH 10 
EDTA (10 μΜ), pH 7.4 
Chymostatin (30 μg/ml), pH 7.4 
Excess non-labelled LDL, pH 7.4 
Native (non-incubated) LDL 
without myocyte lysate 
1.93±0.17 
2.06 ±0.35 
1.66±0.19 
1.49 ±0.06 
1.60 ±0.02 
2.10±0.19 
with myocyte lysate 
8.45 ±0.94 
7.84 ±0.06 
4.97 ±0.35 
5.72±0.19 
5.16±0.33 
4.93 ±0.38 
5.00 ±0.05 
3.90 ±0.49 
125I-Labelled LDL (100 μg protein/ml) was incubated with myocyte lysate (Mb 4 μΜ) for 22 h at 37°C. Myocyte lysate-modified, control and native 
125I-labelled LDL were diluted to 10 μg protein/ml in serum-containing medium and incubated with mouse peritoneal macrophages (1 X106 
peritoneal cells/ml) or in cell-free wells for 22 h at 37°C. Excess non-labelled LDL was added to some of the wells. The means ± S.E.M. are shown 
but are representative of two independent experiments. 
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demonstrate that there are differences in the modification of 
the apolipoprotein B-100, which results in differential extents 
of degradation by macrophages. 
Myocyte lysate modification of LDL results in only mod-
erate modification of the surface charge on the apolipoprotein 
B-100. This can clearly be seen by agarose gel electrophoresis 
which shows only a small increase in electrophoretic mobility. 
Carpenter et al. [31] demonstrated that the electrophoretic 
mobility of oxidised LDL increases before the uptake by mac-
rophages. It was therefore expected that uptake by macro-
phages, being dependent on the modification of the apolipo-
protein B-100, would be minimal. The oxidation and uptake 
by macrophages promoted by the various oxidation states of 
myoglobin was inhibited totally by the chain breaking antiox-
idant BHT whereas for the myocyte lysate-modified LDL, the 
increase in electrophoretic mobility was inhibited, but the in-
crease in macrophage uptake was not. 
Protease (type XIV) was used in the isolation procedure, a 
modification of that of Powell et al. [23]. It was a possibility 
that this protease was damaging the LDL and increasing the 
uptake by macrophages. However, myocyte lysate prepared 
without protease also resulted in increased LDL uptake by 
macrophages. Therefore protease activity from the isolation 
procedure was eliminated as a possibility. Leake et al. [25] 
reported that proteases present in sonicated macrophages par-
tially degraded the apolipoprotein B-100 of LDL at acidic pH, 
and the resultant modified LDL was taken up much faster 
than control LDL, presumably because it was aggregated 
[27]. The use of protease inhibitors indicated that lysosomal 
cathepsin B and cathepsin D were involved. Similarly, in the 
myocyte lysate preparations lysosomal enzymes will be re-
leased on sonication and be present in the final myocyte ly-
sate. Since lysosomes in myocytes contain cathepsin D [28], 
lysosomal proteolytic enzymes released by sonication, present 
in the myocyte lysate, may cause partial proteolysis of the 
apolipoprotein B-100 and result in aggregation of LDL par-
ticles and uptake by macrophages. Preliminary work involving 
Sepharose CL-4B columns indicated that the myocyte-modi-
fied LDL was not aggregated. 
Further complications pertain since Bagby et al. [32] re-
ported lipoprotein lipase activity in sonicated rat heart myo-
cytes. The effects of enzymes which exist in the cells of the 
arterial wall have been studied by Aviram et al. [33]. Incuba-
tion of LDL and lipoprotein lipase led to modification of the 
lipoprotein core triglycerides. Lipoprotein lipase reduced the 
core triglyceride content without producing marked differen-
ces in the size, charge, or in the lipid peroxide content in 
comparison to native LDL. The triglyceride-depleted forms 
of LDL were degraded at approximately twice the rate of 
native LDL by macrophages [33]. Furthermore, phospho-
lipase A2 [34] and phospholipase D [35] can also modify 
LDL to increase its uptake by macrophages. The non-oxida-
tive modification of LDL by myocyte lysate was pH-depend-
ent, and this may once again indicate a role for acidic pro-
teases and/or lipases. However, further extensive 
investigations would be required to elucidate the specific en-
zymes involved. 
The addition of polyinosinic acid (a competing ligand for 
the type A scavenger receptor) did not result in a decrease in 
the degradation of myocyte-lysate modified LDL, therefore 
indicating the uptake was not via the scavenger receptor 
type A of mouse peritoneal macrophages that recognise oxi-
dised LDL [7]. The addition of excess unlabelled LDL to 
competitively block the LDL receptor did not greatly reduce 
the degradation of 125I-labelled myocyte lysate-modified LDL. 
It can therefore be concluded that uptake is via some other 
mechanism than the LDL receptor, unless myocyte lysate-
modified LDL binds to the LDL receptor with much higher 
affinity than does LDL itself. 
The mechanism of the uptake of myocyte lysate-modified 
LDL by macrophages is complex and it is not yet clear what 
mechanism of modification of apolipoprotein B-100 is in-
volved, but what is clear is that it is not an oxidative process. 
Recent studies have been described in which non-oxidative 
modification of native LDL is induced by its oxidatively 
modified form [12] and the presence of these modified forms 
have been identified in the blood of patients with cardiovas-
cular disease [13]. Other workers have shown the binding of 
angiotensin II to the surface of LDL and the uptake of an-
giotensin II-modified LDL by macrophages via the scavenger 
receptor [14]. 
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